ArticleJournal of cystic fibrosis : official journal of the European Cystic Fibrosis Society2021
Elexacafator/tezacaftor/ivacaftor resolves subfertility in females with CF: A two center case series.
Article in Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 62 citations in OpenAlex.
- Maternal and fetal outcomes associated with CFTR modulator use during pregnancy: a scoping review.European respiratory review : an official journal of the European Respiratory Society · 2026Article
- Maternal, Infant, Reproductive and Child Health in Cystic Fibrosis (MATRIARCH_CF): a prospective, observational study to evaluate pregnancy and parenthood in females with cystic fibrosis and health of the offspring in the CFTR-modulator era.BMJ open respiratory research · 2026Observational
- Assessing the Need for Reproductive Genetic Counseling Among Adults with Cystic Fibrosis.Research square · 2026Article
- Case Series on the Combined Therapy with Elexacaftor/Tezacaftor/Ivacaftor During Pregnancy in Women with Severe Cystic Fibrosis: A Retrospective Report from an Italian Centre.Journal of clinical medicine · 2025Article
- Contraceptive use and pregnancy in cystic fibrosis: Survey findings from 10 cystic fibrosis centers.Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society · 2025Article
- Development and clinical implementation of an LC-HRMS method for ivacaftor, lumacaftor, tezacaftor and elexacaftor in human plasma and breast milk.Analytical and bioanalytical chemistry · 2024Article
- Cystic fibrosis.Nature reviews. Disease primers · 2024Review
- Paediatric Thoracic Imaging in Cystic Fibrosis in the Era of Cystic Fibrosis Transmembrane Conductance Regulator Modulation.Children (Basel, Switzerland) · 2024Review
- Ovarian reserve in women with cystic fibrosis: is this a cause of sub-fertility?Journal of ovarian research · 2023Article
- Reproductive Counseling and Care in Cystic Fibrosis: A Multidisciplinary Approach for a New Therapeutic Era.Life (Basel, Switzerland) · 2023Review
- Elexacaftor-Tezacaftor-Ivacaftor: A Life-Changing Triple Combination of CFTR Modulator Drugs for Cystic Fibrosis.Pharmaceuticals (Basel, Switzerland) · 2023Review
- Post-approval studies with the CFTR modulators Elexacaftor-Tezacaftor-Ivacaftor.Frontiers in pharmacology · 2023Review
- Ocular development after highly effective modulator treatment early in life.Frontiers in pharmacology · 2023Review
- Elexacaftor/Tezacaftor/Ivacaftor Disrupts Respiratory Tract Development in a Murine Fetal Lung Explant Model.American journal of respiratory cell and molecular biology · 2022Article
- Use of elexacaftor/tezacaftor/ivacaftor among cystic fibrosis lung transplant recipients.Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society · 2022Article
- Drug exposure to infants born to mothers taking Elexacaftor, Tezacaftor, and Ivacaftor.Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society · 2022Article
- Prospectively evaluating maternal and fetal outcomes in the era of CFTR modulators: the MAYFLOWERS observational clinical trial study design.BMJ open respiratory research · 2022Article
- Family-building and parenting considerations for people with cystic fibrosis.Pediatric pulmonology · 2022Review
- Management of Individual Patient Expectations When Starting with Highly Effective CFTR Modulators.Journal of personalized medicine · 2021Review
- New Therapies to Correct the Cystic Fibrosis Basic Defect.International journal of molecular sciences · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
Abstract
Infertility and subfertility are commonly faced by females with cystic fibrosis (FwCF) and resulting in decreased contraceptive use and increased utilization of reproductive technologies. Elexacaftor-tezacaftor-ivacaftor (ETI) is a CFTR modulator that affects common causes of subfertility. Two CF centers conducted a retrospective chart review on females with CF who were receiving ETI and became pregnant. We analyzed obstetrical-gynecological history, genotype, and clinical response to ETI therapy. Fourteen FwCF on ETI became pregnant. Half (7) of the FwCFs were previously attempting to conceive, but only three were using contraceptives. Four FwCF had a history of infertility; two were reconsidering use of reproductive technologies (IUI). Patients achieved conception at mean 8 weeks after initiating ETI. ETI may lessen CF-associated factors that affect fertility; however, its exact mechanism is unknown. This warrants counseling on contraceptive use and family planning prior to initiation of therapy and at routine intervals while utilizing ETI.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.